Dynavax Technologies Corp (DVAX) 29.73 $DVAX
Will Allergan's (AGN) Earnings Streak Continue in 2Q? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 04, 5:02PM CDT
Allergan's (AGN) top as well as bottom line should continue to be driven by the acquisition of Botox-maker Allergan Inc. as well as other acquisitions.
BDSI: 7.81 (+0.17), DVAX: 29.73 (-0.48), AGN: 336.64 (+5.64), TEVA: 71.19 (+0.50)
Dynavax Technologies Shares Up 33.3% Since SmarTrend's Buy Recommendation (DVAX)
Comtex SmarTrend(R) - Fri Jul 31, 9:26AM CDT
SmarTrend identified an Uptrend for Dynavax Technologies (NASDAQ
VAX) on May 22nd, 2015 at $21.88. In approximately 2 months, Dynavax Technologies has returned 33.35% as of today's recent price of $29.17.
DVAX: 29.73 (-0.48)
Dynavax concludes public offering of 5.23m common stock, including full exercise of over-allotment option
M2 - Wed Jul 29, 5:00AM CDT
Biopharmaceutical company Dynavax Technologies (NASDAQ VAX) disclosed on Tuesday that it has completed the public offering of 5,227,273 shares of its common stock.
DVAX: 29.73 (-0.48)
Dynavax Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
Marketwired - Tue Jul 28, 7:00AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the completion of an underwritten public offering of 5,227,273 shares of its common stock, including 681,818 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offered by Dynavax at a price to the public of $27.50 per share. The net proceeds to Dynavax from this offering were approximately $135 million, after deducting the underwriting discount and other estimated offering expenses payable by Dynavax. Dynavax anticipates using the net proceeds from the proposed offering to fund activities associated with completing the ongoing Phase 3 HBV-23 study of HEPLISAV-B(TM), seeking regulatory approval of HEPLISAV-B in the United States, and preparing for the anticipated U.S. commercial launch of HEPLISAV-B, should HEPLISAV-B gain approval by the Food and Drug Administration. In addition, net proceeds from the offering will support continuing the clinical development of our investigational cancer immunotherapeutic product candidate, SD-101, and for other general corporate purposes, including working capital.
DVAX: 29.73 (-0.48)
Dynavax Prices Public Offering of Common Stock
Marketwired - Wed Jul 22, 7:15AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of a previously announced underwritten public offering of 4,545,455 shares of its common stock, offered at a price to the public of $27.50 per share. The gross proceeds to Dynavax from this offering are expected to be approximately $125 million, before deducting the underwriting discount and other estimated offering expenses payable by Dynavax. Dynavax has granted the underwriters a 30-day option to purchase at the public offering price up to an aggregate of 681,818 additional shares of its common stock to cover over-allotments, if any. The offering is expected to close on or about July 27, 2015, subject to customary closing conditions. Dynavax anticipates using the net proceeds from the proposed offering to fund activities associated with completing the ongoing Phase 3 HBV-23 study of HEPLISAV-B(TM), seeking regulatory approval of HEPLISAV-B in the United States, and preparing for the anticipated U.S. commercial launch of HEPLISAV-B, should HEPLISAV-B gain approval by the Food and Drug Administration. In addition, net proceeds from the offering will support continuing the clinical development of our investigational cancer immunotherapeutic product candidate, SD-101, and for other general corporate purposes, including working capital.
DVAX: 29.73 (-0.48)
Dynavax plans to launch public offering of common shares
M2 - Wed Jul 22, 4:43AM CDT
Biopharmaceutical company Dynavax Technologies (NASDAQ VAX) announced on Tuesday that it plans to offer and sell shares of its common stock in a public offering.
DVAX: 29.73 (-0.48)
Dynavax Announces Proposed Public Offering of Common Stock
Marketwired - Tue Jul 21, 3:01PM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. Dynavax also expects to grant the underwriters a 30-day option to purchase additional shares of common stock to cover over-allotments, if any. Dynavax anticipates using the net proceeds from the proposed offering to fund activities associated with completing the ongoing Phase 3 HBV-23 study of HEPLISAV-B(TM), seeking regulatory approval of HEPLISAV-B in the United States, and preparing for the anticipated U.S. commercial launch of HEPLISAV-B, should HEPLISAV-B gain approval by the Food and Drug Administration. In addition, net proceeds from the offering will support continuing the clinical development of our investigational cancer immunotherapeutic product candidate, SD-101, and for other general corporate purposes, including working capital.
DVAX: 29.73 (-0.48)
Why Shares in Dynavax Technologies Corp Are Soaring 10% Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 09, 1:01PM CDT
Source: Dynavax Technologies Corporation A decision by an independent monitoring board to continue the phase 3 trial of Dynavax Technologies Corp.'s hepatitis B vaccine led to the company's shares jumping by 10% earlier today. Improving...
DVAX: 29.73 (-0.48)
Dynavax Announces Third Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM) and Updates Financial Status
Marketwired - Thu Jul 09, 8:01AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the independent Data and Safety Monitoring Board (DSMB) charged with periodically reviewing safety data from HBV-23, the ongoing Phase 3 clinical study of HEPLISAV-B, Dynavax's investigational adult hepatitis B vaccine, has completed its third prespecified review and has recommended that the study continue unchanged.
DVAX: 29.73 (-0.48)
Dynavax Technologies (DVAX) in Focus: Stock Up 8.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 07, 8:46AM CDT
Dynavax Technologies Corporation (DVAX) was a big mover last session, as the company saw its shares rise over 8% on the day.
DVAX: 29.73 (-0.48), AMAG: 69.36 (+2.26)
4 Big-Volume Stocks to Trade for Breakouts
at The Street - Tue Jul 07, 5:00AM CDT
These stocks rising on unusual volume could be within range of triggering breakout trades.
DVAX: 29.73 (-0.48), XON: 68.71 (+3.37), PETX: 17.64 (+0.07), EHTH: 15.77 (-0.13)
Global Travel Vaccines Market 2015-2019: with Janssen Pharmaceuticals, Pfizer and Novartis Dominating
M2 - Fri Jun 19, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cn7mmg/global_travel) has announced the addition of the "Global Travel Vaccines Market 2015-2019" report to their offering. Commenting on the report, an analyst from the author's team said: One major trend upcoming in this market is the public-private initiatives undertaken in developing countries for scheduling and supplying vaccines to the target population. Organizations such as the GAVI, the WHO, and UNICEF have developed partnerships with governments and are involved in providing vaccines to remove the misconceptions about vaccination and immunization. According to the report, the growing demand for vaccines among international travelers is the major contributor to the growth of the demand. Meningococcal disease, hepatitis, and Japanese encephalitis vaccines are designated as traveler's vaccines. Globally, various government bodies have mandated the immunization of travelers visiting meningitis-prone areas with meningococcal vaccines to prevent the spread of infection and avert any chances of epidemic outbreaks. The analysts forecast the Global Travel Vaccines market to grow at a CAGR of 7.78 percent over the period 2014-2019. Key Vendors - GlaxoSmithKline - Merck & Co. - Novartis - Sanofi Other Prominent Vendors - Beijing Minhai Biotechnology - Bharat Biotech - Bio Med - Crucell - CSL - Dynavax Technologies - Emergent Biosolutions - Green Signal Bio Pharma - Hualan Biological Engineering - Imunoloski Zavod - Indian Immunologicals - Janssen Pharmaceuticals - JN International Medical - Kaketsuken - LG Life Sciences - Novavax - Nuron Biotech - Panacea Biotec - Pfizer - S K Chemicals - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Vacunas Finlay - Valneva For more information visit http://www.researchandmarkets.com/research/cn...bal_travel About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
DVAX: 29.73 (-0.48), EBS: 32.73 (-0.27), MRK: 59.10 (+0.40), GSK: 44.17 (+0.72), SVA: 5.20 (-0.05), NVS: 103.25 (-0.32)
Dynavax to Present at the William Blair 35th Annual Growth Stock Health Care Conference
Marketwired - Tue Jun 09, 8:01AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that Michael Ostrach, the Company's Chief Financial Officer, will present at the William Blair 35th Annual Growth Stock Conference on Thursday, June 11, 2015 at 8:00 AM Central Time at the Four Seasons Hotel in Chicago.
DVAX: 29.73 (-0.48)
Global Anthrax Pipeline Review, H1 2015 - 33 Companies & 29 Drug Profiles
M2 - Mon Jun 08, 8:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nbhb3h/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Aradigm Corporation - Bavarian Nordic A/S - Bristol-Myers Squibb Company - ContraFect Corporation - Dynavax Technologies Corporation - Elusys Therapeutics, Inc. - Emergent BioSolutions Inc. - Evolva SA - Green Cross Corporation - Grifols, S.A. - Hawaii Biotech, Inc. - iBio, Inc. - Immunovaccine, Inc. - Innovative Biologics, Inc. - Microbiotix, Inc. - NanoBio Corporation - Navigen Pharmaceuticals, Inc. - Oragenics, Inc. - PaxVax - Pfenex Inc. - Planet Biotechnology Inc. - Protein Potential, LLC - ProThera Biologics, LLC. - PsiOxus Therapeutics, Ltd. - Revivicor, Inc. - SelectX Pharmaceuticals, Inc. - Soligenix, Inc. - Summit Corporation plc - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - The Medicines Company - Vaxin, Inc. For more information visit http://www.researchandmarkets.com/research/nbhb3h/anthrax
DVAX: 29.73 (-0.48), TTPH: 46.50 (-0.39), EBS: 32.73 (-0.27), ADRO: 24.33 (+0.19), IBIO: 0.65 (-0.03), BMY: 65.06 (+0.22), SMMT: 13.00 (-0.29), PFNX: 20.56 (-0.30), OGEN: 3.21 (-0.03)
Dow 30 Stock Roundup: Intel to Buy Altera, UnitedHealth Hikes Quarterly Dividend - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Jun 05, 12:26PM CDT
The Dow secured gains and took losses during a volatile week of trading. Stocks ended the first trading day of June with modest gains following mixed economic reports.
DVAX: 29.73 (-0.48), FEYE: 44.56 (+1.11), ADP: 81.84 (+1.16), V: 74.98 (-0.29), MRK: 59.10 (+0.40), ALTR: 50.22 (+0.17), UNH: 123.92 (+3.08), XOM: 77.17 (unch), INTC: 29.12 (-0.01), BA: 144.95 (+1.41), CVX: 84.03 (-1.18)
Merck's Keytruda under Priority Review for Lung Cancer - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jun 02, 9:30AM CDT
Merck (MRK) should receive a response from the FDA by Oct 2.
DVAX: 29.73 (-0.48), GILD: 118.66 (-0.21), MRK: 59.10 (+0.40), AMGN: 176.44 (+1.64)
Merck and Dynavax team up in cancer clinical trials
Seeking Alpha - at Seeking Alpha - Mon Jun 01, 3:20PM CDT
DVAX: 29.73 (-0.48), MRK: 59.10 (+0.40)
Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies
Business Wire - Mon Jun 01, 7:30AM CDT
--Collaboration Includes First-in-human Study for MK-1966, a New Investigational Anti-interleukin-10 (anti-IL-10) Immunomodulator from Merck's Rapidly Growing Immuno-oncology Pipeline
DVAX: 29.73 (-0.48), MRK: 59.10 (+0.40)
Trio Of Small Biotechs With Upcoming 2015 Catalysts And Enormous Long-Term Potential
MedTechBio - at Seeking Alpha - Wed May 27, 7:22AM CDT
DVAX: 29.73 (-0.48), GERN: 4.02 (+0.02), CNAT: 4.31 (-0.10)
Dynavax Technologies Is A Bargain Now
Emerging Equities - at Seeking Alpha - Thu May 07, 3:11PM CDT
DVAX: 29.73 (-0.48), MRK: 59.10 (+0.40), GSK: 44.17 (+0.72)
Will Allergan's (AGN) Earnings Streak Continue in 2Q? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 04, 5:02PM CDT
Allergan's (AGN) top as well as bottom line should continue to be driven by the acquisition of Botox-maker Allergan Inc. as well as other acquisitions.
BDSI: 7.81 (+0.17), DVAX: 29.73 (-0.48), AGN: 336.64 (+5.64), TEVA: 71.19 (+0.50)
Dynavax Technologies Shares Up 33.3% Since SmarTrend's Buy Recommendation (DVAX)
Comtex SmarTrend(R) - Fri Jul 31, 9:26AM CDT
SmarTrend identified an Uptrend for Dynavax Technologies (NASDAQ
VAX) on May 22nd, 2015 at $21.88. In approximately 2 months, Dynavax Technologies has returned 33.35% as of today's recent price of $29.17. DVAX: 29.73 (-0.48)
Dynavax concludes public offering of 5.23m common stock, including full exercise of over-allotment option
M2 - Wed Jul 29, 5:00AM CDT
Biopharmaceutical company Dynavax Technologies (NASDAQ
VAX) disclosed on Tuesday that it has completed the public offering of 5,227,273 shares of its common stock. DVAX: 29.73 (-0.48)
Dynavax Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
Marketwired - Tue Jul 28, 7:00AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the completion of an underwritten public offering of 5,227,273 shares of its common stock, including 681,818 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offered by Dynavax at a price to the public of $27.50 per share. The net proceeds to Dynavax from this offering were approximately $135 million, after deducting the underwriting discount and other estimated offering expenses payable by Dynavax. Dynavax anticipates using the net proceeds from the proposed offering to fund activities associated with completing the ongoing Phase 3 HBV-23 study of HEPLISAV-B(TM), seeking regulatory approval of HEPLISAV-B in the United States, and preparing for the anticipated U.S. commercial launch of HEPLISAV-B, should HEPLISAV-B gain approval by the Food and Drug Administration. In addition, net proceeds from the offering will support continuing the clinical development of our investigational cancer immunotherapeutic product candidate, SD-101, and for other general corporate purposes, including working capital.
DVAX: 29.73 (-0.48)
Dynavax Prices Public Offering of Common Stock
Marketwired - Wed Jul 22, 7:15AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of a previously announced underwritten public offering of 4,545,455 shares of its common stock, offered at a price to the public of $27.50 per share. The gross proceeds to Dynavax from this offering are expected to be approximately $125 million, before deducting the underwriting discount and other estimated offering expenses payable by Dynavax. Dynavax has granted the underwriters a 30-day option to purchase at the public offering price up to an aggregate of 681,818 additional shares of its common stock to cover over-allotments, if any. The offering is expected to close on or about July 27, 2015, subject to customary closing conditions. Dynavax anticipates using the net proceeds from the proposed offering to fund activities associated with completing the ongoing Phase 3 HBV-23 study of HEPLISAV-B(TM), seeking regulatory approval of HEPLISAV-B in the United States, and preparing for the anticipated U.S. commercial launch of HEPLISAV-B, should HEPLISAV-B gain approval by the Food and Drug Administration. In addition, net proceeds from the offering will support continuing the clinical development of our investigational cancer immunotherapeutic product candidate, SD-101, and for other general corporate purposes, including working capital.
DVAX: 29.73 (-0.48)
Dynavax plans to launch public offering of common shares
M2 - Wed Jul 22, 4:43AM CDT
Biopharmaceutical company Dynavax Technologies (NASDAQ
VAX) announced on Tuesday that it plans to offer and sell shares of its common stock in a public offering. DVAX: 29.73 (-0.48)
Dynavax Announces Proposed Public Offering of Common Stock
Marketwired - Tue Jul 21, 3:01PM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. Dynavax also expects to grant the underwriters a 30-day option to purchase additional shares of common stock to cover over-allotments, if any. Dynavax anticipates using the net proceeds from the proposed offering to fund activities associated with completing the ongoing Phase 3 HBV-23 study of HEPLISAV-B(TM), seeking regulatory approval of HEPLISAV-B in the United States, and preparing for the anticipated U.S. commercial launch of HEPLISAV-B, should HEPLISAV-B gain approval by the Food and Drug Administration. In addition, net proceeds from the offering will support continuing the clinical development of our investigational cancer immunotherapeutic product candidate, SD-101, and for other general corporate purposes, including working capital.
DVAX: 29.73 (-0.48)
Why Shares in Dynavax Technologies Corp Are Soaring 10% Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 09, 1:01PM CDT
Source: Dynavax Technologies Corporation A decision by an independent monitoring board to continue the phase 3 trial of Dynavax Technologies Corp.'s hepatitis B vaccine led to the company's shares jumping by 10% earlier today. Improving...
DVAX: 29.73 (-0.48)
Dynavax Announces Third Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM) and Updates Financial Status
Marketwired - Thu Jul 09, 8:01AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the independent Data and Safety Monitoring Board (DSMB) charged with periodically reviewing safety data from HBV-23, the ongoing Phase 3 clinical study of HEPLISAV-B, Dynavax's investigational adult hepatitis B vaccine, has completed its third prespecified review and has recommended that the study continue unchanged.
DVAX: 29.73 (-0.48)
Dynavax Technologies (DVAX) in Focus: Stock Up 8.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 07, 8:46AM CDT
Dynavax Technologies Corporation (DVAX) was a big mover last session, as the company saw its shares rise over 8% on the day.
DVAX: 29.73 (-0.48), AMAG: 69.36 (+2.26)
4 Big-Volume Stocks to Trade for Breakouts
at The Street - Tue Jul 07, 5:00AM CDT
These stocks rising on unusual volume could be within range of triggering breakout trades.
DVAX: 29.73 (-0.48), XON: 68.71 (+3.37), PETX: 17.64 (+0.07), EHTH: 15.77 (-0.13)
Global Travel Vaccines Market 2015-2019: with Janssen Pharmaceuticals, Pfizer and Novartis Dominating
M2 - Fri Jun 19, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cn7mmg/global_travel) has announced the addition of the "Global Travel Vaccines Market 2015-2019" report to their offering. Commenting on the report, an analyst from the author's team said: One major trend upcoming in this market is the public-private initiatives undertaken in developing countries for scheduling and supplying vaccines to the target population. Organizations such as the GAVI, the WHO, and UNICEF have developed partnerships with governments and are involved in providing vaccines to remove the misconceptions about vaccination and immunization. According to the report, the growing demand for vaccines among international travelers is the major contributor to the growth of the demand. Meningococcal disease, hepatitis, and Japanese encephalitis vaccines are designated as traveler's vaccines. Globally, various government bodies have mandated the immunization of travelers visiting meningitis-prone areas with meningococcal vaccines to prevent the spread of infection and avert any chances of epidemic outbreaks. The analysts forecast the Global Travel Vaccines market to grow at a CAGR of 7.78 percent over the period 2014-2019. Key Vendors - GlaxoSmithKline - Merck & Co. - Novartis - Sanofi Other Prominent Vendors - Beijing Minhai Biotechnology - Bharat Biotech - Bio Med - Crucell - CSL - Dynavax Technologies - Emergent Biosolutions - Green Signal Bio Pharma - Hualan Biological Engineering - Imunoloski Zavod - Indian Immunologicals - Janssen Pharmaceuticals - JN International Medical - Kaketsuken - LG Life Sciences - Novavax - Nuron Biotech - Panacea Biotec - Pfizer - S K Chemicals - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Vacunas Finlay - Valneva For more information visit http://www.researchandmarkets.com/research/cn...bal_travel About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
DVAX: 29.73 (-0.48), EBS: 32.73 (-0.27), MRK: 59.10 (+0.40), GSK: 44.17 (+0.72), SVA: 5.20 (-0.05), NVS: 103.25 (-0.32)
Dynavax to Present at the William Blair 35th Annual Growth Stock Health Care Conference
Marketwired - Tue Jun 09, 8:01AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that Michael Ostrach, the Company's Chief Financial Officer, will present at the William Blair 35th Annual Growth Stock Conference on Thursday, June 11, 2015 at 8:00 AM Central Time at the Four Seasons Hotel in Chicago.
DVAX: 29.73 (-0.48)
Global Anthrax Pipeline Review, H1 2015 - 33 Companies & 29 Drug Profiles
M2 - Mon Jun 08, 8:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nbhb3h/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Aradigm Corporation - Bavarian Nordic A/S - Bristol-Myers Squibb Company - ContraFect Corporation - Dynavax Technologies Corporation - Elusys Therapeutics, Inc. - Emergent BioSolutions Inc. - Evolva SA - Green Cross Corporation - Grifols, S.A. - Hawaii Biotech, Inc. - iBio, Inc. - Immunovaccine, Inc. - Innovative Biologics, Inc. - Microbiotix, Inc. - NanoBio Corporation - Navigen Pharmaceuticals, Inc. - Oragenics, Inc. - PaxVax - Pfenex Inc. - Planet Biotechnology Inc. - Protein Potential, LLC - ProThera Biologics, LLC. - PsiOxus Therapeutics, Ltd. - Revivicor, Inc. - SelectX Pharmaceuticals, Inc. - Soligenix, Inc. - Summit Corporation plc - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - The Medicines Company - Vaxin, Inc. For more information visit http://www.researchandmarkets.com/research/nbhb3h/anthrax
DVAX: 29.73 (-0.48), TTPH: 46.50 (-0.39), EBS: 32.73 (-0.27), ADRO: 24.33 (+0.19), IBIO: 0.65 (-0.03), BMY: 65.06 (+0.22), SMMT: 13.00 (-0.29), PFNX: 20.56 (-0.30), OGEN: 3.21 (-0.03)
Dow 30 Stock Roundup: Intel to Buy Altera, UnitedHealth Hikes Quarterly Dividend - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Jun 05, 12:26PM CDT
The Dow secured gains and took losses during a volatile week of trading. Stocks ended the first trading day of June with modest gains following mixed economic reports.
DVAX: 29.73 (-0.48), FEYE: 44.56 (+1.11), ADP: 81.84 (+1.16), V: 74.98 (-0.29), MRK: 59.10 (+0.40), ALTR: 50.22 (+0.17), UNH: 123.92 (+3.08), XOM: 77.17 (unch), INTC: 29.12 (-0.01), BA: 144.95 (+1.41), CVX: 84.03 (-1.18)
Merck's Keytruda under Priority Review for Lung Cancer - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jun 02, 9:30AM CDT
Merck (MRK) should receive a response from the FDA by Oct 2.
DVAX: 29.73 (-0.48), GILD: 118.66 (-0.21), MRK: 59.10 (+0.40), AMGN: 176.44 (+1.64)
Merck and Dynavax team up in cancer clinical trials
Seeking Alpha - at Seeking Alpha - Mon Jun 01, 3:20PM CDT
DVAX: 29.73 (-0.48), MRK: 59.10 (+0.40)
Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies
Business Wire - Mon Jun 01, 7:30AM CDT
--Collaboration Includes First-in-human Study for MK-1966, a New Investigational Anti-interleukin-10 (anti-IL-10) Immunomodulator from Merck's Rapidly Growing Immuno-oncology Pipeline
DVAX: 29.73 (-0.48), MRK: 59.10 (+0.40)
Trio Of Small Biotechs With Upcoming 2015 Catalysts And Enormous Long-Term Potential
MedTechBio - at Seeking Alpha - Wed May 27, 7:22AM CDT
DVAX: 29.73 (-0.48), GERN: 4.02 (+0.02), CNAT: 4.31 (-0.10)
Dynavax Technologies Is A Bargain Now
Emerging Equities - at Seeking Alpha - Thu May 07, 3:11PM CDT
DVAX: 29.73 (-0.48), MRK: 59.10 (+0.40), GSK: 44.17 (+0.72)
